↓ Skip to main content

Long-term use of metformin and the molecular subtype in invasive breast carcinoma patients – a retrospective study of clinical and tumor characteristics

Overview of attention for article published in BMC Cancer, April 2014
Altmetric Badge

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
27 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Long-term use of metformin and the molecular subtype in invasive breast carcinoma patients – a retrospective study of clinical and tumor characteristics
Published in
BMC Cancer, April 2014
DOI 10.1186/1471-2407-14-298
Pubmed ID
Authors

Nikola Besic, Nika Satej, Ivica Ratosa, Andreja Gojkovic Horvat, Tanja Marinko, Barbara Gazic, Rok Petric

Abstract

Metformin may exhibit inhibitory effects on cancer cells by inhibiting mTOR signaling pathway. The aim of our retrospective study was to examine if patients with breast carcinoma (BC) and diabetes mellitus (DM) receiving metformin have a lower stage of carcinoma in comparison to patients not receiving metformin, and if the use of metformin correlates with the molecular subtype of BC.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 27 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Slovenia 1 4%
Unknown 26 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 30%
Student > Bachelor 6 22%
Other 3 11%
Student > Doctoral Student 2 7%
Professor 1 4%
Other 4 15%
Unknown 3 11%
Readers by discipline Count As %
Medicine and Dentistry 14 52%
Biochemistry, Genetics and Molecular Biology 3 11%
Pharmacology, Toxicology and Pharmaceutical Science 3 11%
Agricultural and Biological Sciences 2 7%
Nursing and Health Professions 1 4%
Other 0 0%
Unknown 4 15%